Share on StockTwits

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) saw unusually large options trading on Monday. Traders acquired 3,640 put options on the company, Analyst Ratings Network reports. This is an increase of 1,059% compared to the typical volume of 314 put options.

In other BioMarin Pharmaceutical news, CFO Daniel K. Spiegelman unloaded 2,229 shares of the stock on the open market in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $64.00, for a total transaction of $142,656.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on BMRN shares. Analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Friday. They now have a $68.00 price target on the stock. Separately, analysts at Credit Suisse upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. They now have a $73.00 price target on the stock, up previously from $61.74. Nine investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $81.07.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 4.55% on Monday, hitting $61.65. The stock had a trading volume of 1,187,663 shares. BioMarin Pharmaceutical has a 1-year low of $55.04 and a 1-year high of $84.25. The stock has a 50-day moving average of $60.71 and a 200-day moving average of $67.06. The company’s market cap is $8.996 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings data on Thursday, May 1st. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.43. The company had revenue of $151.60 million for the quarter, compared to the consensus estimate of $145.16 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 18.5% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.72 EPS for the current fiscal year.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.